The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs von van der Velden, D. L., Hoes, L. R., van der Wijngaart, H., van Berge Henegouwen, J. M., van Werkhoven, E., Roepman, P., Schilsky, R. L., de Leng, W. W. J., Huitema, A. D. R., Nuijen, B., Nederlof, P. M., van Herpen, C. M. L., de Groot, D. J. A., Devriese, L. A., Hoeben, A., de Jonge, M. J. A., Chalabi, M., Smit, E. F., de Langen, A. J., Mehra, N., Labots, M., Kapiteijn, E., Sleijfer, S., Cuppen, E., Verheul, H. M. W., Gelderblom, H., Voest, E. E.

Volltext

Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 st... von Goey, K.K.H., Elias, S.G., van Tinteren, H., Laclé, M.M., Willems, S.M., Offerhaus, G.J.A., de Leng, W.W.J., Strengman, E., ten Tije, A.J., Creemers, G.-J. M., van der Velden, A., de Jongh, F.E., Erdkamp, F.L.G., Tanis, B.C., Punt, C.J.A., Koopman, M.

Volltext

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer von van Berge Henegouwen, J.M., Jebbink, M., Hoes, L.R., van der Wijngaart, H., Zeverijn, L.J., van der Velden, D.L., Roepman, P., de Leng, W.W.J., Jansen, A.M.L., van Werkhoven, E., van der Noort, V., van der Wekken, A.J., de Langen, A.J., Voest, E.E., Verheul, H.M.W., Smit, E.F., Gelderblom, H.

Volltext

Cyclooxygenase-2 dependent regulation of E-cadherin through the transcription repressors Snail and ZEB1 is limited to conventional gastric cancers cell lines von Sitarz, R, de Leng, W.W.J, Leguit, R, Morsink, F.H.M, Polkowski, W.P, Maciejewski, R, Offerhaus, G.J.A, Milne, A.N

Volltext

PO-467 Unclarified cases of microsatellite instability analyses for lynch syndrome diagnostics von Ma, H, Geurts-Giele, WRR, Alkemade, M, Koudijs, M, Letteboer, TGW, Dinjens, WNM, Morsink, FHM, Offerhaus, GJA, Brosens, LAA, De Leng, WWJ

Volltext

Formalin-fixed, paraffin-embedded-targeted locus capture: a next-generation sequencing technology for accurate DNA-based gene fusion detection in bone and soft tissue tumors von Stelloo, E., Meijers, R.W.J., Swennenhuis, J.F., Allahyar, A., Hajo, K., Cangiano, M., Leng, W.W.J. de, Helvert, S. van, Meulen, J. van der, Creytens, D., Kempen, L.C. van, Cleton-Jansen, A.M., Bovee, J.V.M.G., Laat, W. de, Splinter, E., Feitsma, H.

Volltext bestellen

Efficacy and safety of panitumumab in patients with RAF/RAS-wild-type glioblastoma: results from the drug rediscovery protocol von Spiekman, I.A.C., Geurts, B.S., Zeverijn, L.J., Wit, G.F. de, Noort, V. van der, Roepman, P., Leng, W.W.J. de, Jansen, A.M.L., Kusters, B., Beerepoot, L., Vos, F.Y.F.L. de, Groot, D.J.A. de, Groot, J.W.B. de, Hoeben, A., Buter, J., Gelderblom, H.A.J., Voest, E.E., Verheul, H.M.W.

Volltext bestellen

Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials von Zeverijn, L.J., Looze, E.J., Thavaneswaran, S., Henegouwen, J.M.V., Simes, R.J., Hoes, L.R., Sjoquist, K.M., Wijngaart, H. van der, Sebastian, L., Geurts, B.S., Lee, C.K., Wit, G.F. de, Espinoza, D., Roepman, P., Lin, F.P., Jansen, A.M.L., Leng, W.W.J. de, Noort, V. van der, Leek, L.V.M., Vos, F.Y.F.L. de, Herpen, C.M.L. van, Gelderblom, H., Verheul, H.M.W., Thomas, D.M., Voest, E.E.

Volltext bestellen

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours von Geurts, B.S., Battaglia, T.W., Henegouwen, J.M.V., Zeverijn, L.J., Wit, G.F. de, Hoes, L.R., Wijngaart, H. van der, Noort, V. van der, Roepman, P., Leng, W.W.J. de, Jansen, A.M.L., Opdam, F.L., Jonge, M.J.A. de, Cirkel, G.A., Labots, M., Hoeben, A., Kerver, E.D., Bins, A.D., Erdkamp, F.G.L., Rooijen, J.M. van, Houtsma, D., Hendriks, M.P., Groot, J.W.B. de, Verheul, H.M.W., Gelderblom, H., Voest, E.E.

Volltext bestellen

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer von Henegouwen, J.M.V., Jebbink, M., Hoes, L.R., Wijngaart, H. van der, Zeverijn, L.J., Velden, D.L. van der, Roepman, P., Leng, W.W.J. de, Jansen, A.M.L., Werkhoven, E. van, Noort, V. van der, Wekken, A.J. van der, Langen, A.J. de, Voest, E.E., Verheul, H.M.W., Smit, E.F., Gelderblom, H.

Volltext bestellen

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer von Henegouwen, J.M.V., Jebbink, M., Hoes, L.R., Wijngaart, H. van der, Zeverijn, L.J., Velden, D.L. van der, Roepman, P., Leng, W.W.J. de, Jansen, A.M.L., Werkhoven, E. van, Noort, V. van der, Wekken, A.J. van der, Langen, A.J. de, Voest, E.E., Verheul, H.M.W., Smit, E.F., Gelderblom, H.

Volltext bestellen

Patients with biallelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types von Wijngaart, H. van der, Hoes, L.R., Henegouwen, J.M.V., Velden, D.L. van der, Zeverijn, L.J., Roepman, P., Werkhoven, E. van, Leng, W.W.J. de, Jansen, A.M.L., Mehra, N., Robbrecht, D.G.J., Labots, M., Groot, D.J.A. de, Hoeben, A., Hamberg, P., Gelderblom, H., Voest, E.E., Verheul, H.M.W.

Volltext bestellen

Multicenter comparison of molecular tumor boards in the Netherlands: definition, composition, methods, and targeted therapy recommendations von Koopman, B., Groen, H.J.M., Ligtenberg, M.J.L., Grunberg, K., Monkhorst, K., Langen, A.J. de, Boelens, M.C., Paats, M.S., Thusen, J.H. von der, Dinjens, W.N.M., Solleveld, N., Wezel, T. van, Gelderblom, H., Hendriks, L.E., Speel, E.J.M., Theunissen, T.E., Kroeze, L.I., Mehra, N., Piet, B., Wekken, A.J. van der, Elst, A. ter, Timens, W., Willems, S.M., Meijers, R.W.J., Leng, W.W.J. de, Lindert, A.S.R. van, Radonic, T., Hashemi, S.M.S., Heideman, D.A.M., Schuuring, E., Kempen, L.C. van

Volltext bestellen